JPWO2020191346A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020191346A5
JPWO2020191346A5 JP2021556432A JP2021556432A JPWO2020191346A5 JP WO2020191346 A5 JPWO2020191346 A5 JP WO2020191346A5 JP 2021556432 A JP2021556432 A JP 2021556432A JP 2021556432 A JP2021556432 A JP 2021556432A JP WO2020191346 A5 JPWO2020191346 A5 JP WO2020191346A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
amino acid
acid sequence
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526738A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023988 external-priority patent/WO2020191346A1/en
Publication of JP2022526738A publication Critical patent/JP2022526738A/ja
Publication of JPWO2020191346A5 publication Critical patent/JPWO2020191346A5/ja
Pending legal-status Critical Current

Links

JP2021556432A 2019-03-21 2020-03-20 アレルギーを治療するためのil-4/il-13経路阻害剤と形質細胞除去の組み合わせ Pending JP2022526738A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962822022P 2019-03-21 2019-03-21
US62/822,022 2019-03-21
US202062957550P 2020-01-06 2020-01-06
US62/957,550 2020-01-06
PCT/US2020/023988 WO2020191346A1 (en) 2019-03-21 2020-03-20 Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy

Publications (2)

Publication Number Publication Date
JP2022526738A JP2022526738A (ja) 2022-05-26
JPWO2020191346A5 true JPWO2020191346A5 (pt) 2023-03-17

Family

ID=70465230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556432A Pending JP2022526738A (ja) 2019-03-21 2020-03-20 アレルギーを治療するためのil-4/il-13経路阻害剤と形質細胞除去の組み合わせ

Country Status (15)

Country Link
US (1) US11964016B2 (pt)
EP (1) EP3941589A1 (pt)
JP (1) JP2022526738A (pt)
KR (1) KR20210143246A (pt)
CN (1) CN113597328A (pt)
AU (1) AU2020240132A1 (pt)
BR (1) BR112021018627A2 (pt)
CA (1) CA3132587A1 (pt)
CL (1) CL2021002410A1 (pt)
CO (1) CO2021013993A2 (pt)
IL (1) IL286470A (pt)
MA (1) MA55372A (pt)
MX (1) MX2021011141A (pt)
SG (1) SG11202109002XA (pt)
WO (1) WO2020191346A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
MX2016011132A (es) 2014-02-28 2016-12-08 Regeneron Pharma Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
EP3506931B1 (en) 2016-09-01 2024-07-31 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3099066A1 (en) 2018-05-13 2019-11-21 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
JP2022543815A (ja) 2019-08-05 2022-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
AU2020398167A1 (en) * 2019-12-06 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
KR20230130681A (ko) * 2021-01-08 2023-09-12 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
CN116963774A (zh) 2021-01-28 2023-10-27 瑞泽恩制药公司 用于治疗细胞因子释放综合征的组合物和方法
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2024173830A2 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
EP0668774A1 (en) 1991-05-03 1995-08-30 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
ATE326239T1 (de) 1998-09-18 2006-06-15 Dynavax Tech Corp Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
AU2001272925A1 (en) 2000-05-26 2001-12-11 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR100572408B1 (ko) 2000-07-26 2006-04-19 가부시키가이샤 호오도 진양성 조성물 및 창상치유촉진 조성물
PT1345624E (pt) 2000-12-22 2006-09-29 Nestle Sa Inducao de tolerancia
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
WO2002092125A1 (en) 2001-05-11 2002-11-21 Novartis Ag Compositions for use in treating ige-associated disorders
US20050074462A1 (en) 2001-05-23 2005-04-07 Duotol Ab Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof
AU2002357770B2 (en) 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
MXPA05005528A (es) 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
JP2006516408A (ja) 2003-02-01 2006-07-06 タノックス インコーポレーテッド 高親和性抗体の生成方法
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
EP1692184B1 (en) 2003-11-07 2012-03-07 Immunex Corporation Antibodies that bind interleukin-4 receptor
CA2550933A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
ES2390344T3 (es) 2003-12-23 2012-11-12 Genentech, Inc. Tratamiento de cáncer con anticuerpos monoclonales anti-IL13 novedosos
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il−4/il−13特異的ポリペプチドおよびその治療上の使用
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
EP2004691A1 (en) 2006-03-22 2008-12-24 Apogenix GmbH Antibody specific for human il-4 for the treament of cancer
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
CA2914170C (en) 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
EP2069403B1 (en) 2006-10-02 2014-05-07 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
RU2500686C2 (ru) * 2007-03-22 2013-12-10 Дженентек, Инк. АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
EP2222709B1 (en) 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
EP2376656A4 (en) 2008-12-01 2012-05-16 Cincinnati Children S Hospital Medical Ct METHODS FOR DETERMINING THE EFFECTIVENESS OF GLUCOCORTICOID TREATMENT OF SOSHOPHILIC OOPHAGITIS
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
WO2011026966A2 (en) 2009-09-07 2011-03-10 Dbv Technologies Method of treating eosinophilic esophagitis
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
WO2011108008A2 (en) 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
ES2894936T3 (es) 2010-06-24 2022-02-16 Viropharma Biologics Llc Métodos de tratamiento para la inflamación del esófago
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
EP2627673B1 (en) 2010-10-15 2017-07-26 Medimmune Limited Therapies for improving pulmonary function
US9334331B2 (en) * 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
EP2661631A4 (en) 2011-01-06 2014-05-21 Childrens Hosp Medical Center EXPRESSION PROFILES FOR OSSOPHAGEAL CYTOKINE IN EOSINOPHILIAN ESOPHAGITIS
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
WO2012177945A2 (en) 2011-06-21 2012-12-27 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140303067A1 (en) 2011-10-06 2014-10-09 N.V. Nutricia Treatment of eosinophilic esophagitis
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
AU2013215332A1 (en) * 2012-01-31 2014-09-04 Genentech, Inc. Anti-Ig-E M1' antibodies and methods using same
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
LT2888281T (lt) 2012-08-21 2018-12-27 Sanofi Biotechnology Astmos gydymo arba profilaktikos būdai, skiriant il-4r antagonistą
CN104995212A (zh) 2012-09-07 2015-10-21 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
EP2953972B1 (en) * 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
MX2015013901A (es) 2013-04-05 2015-12-11 Genentech Inc Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
EP3107575B1 (en) 2014-02-21 2021-09-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
MX2016011132A (es) 2014-02-28 2016-12-08 Regeneron Pharma Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
IL303337A (en) 2014-11-14 2023-08-01 Regeneron Pharma Methods for the treatment of chronic sinusitis with nasal polyps by adding an R4–IL antagonist
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
DK3628687T3 (da) 2014-12-12 2021-10-18 2Seventy Bio Inc Kimære bcma-antigenreceptorer
WO2016130598A1 (en) 2015-02-09 2016-08-18 University Of Florida Research Foundation, Inc. Bi-specific chimeric antigen receptor and uses thereof
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
AU2016248946B2 (en) 2015-04-13 2022-03-10 Pfizer Inc. Therapeutic antibodies and their uses
SG11201707089WA (en) 2015-04-13 2017-10-30 Pfizer Chimeric antigen receptors targeting b-cell maturation antigen
NL2014882B1 (en) 2015-05-29 2017-01-31 Citeq B V Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy.
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
LT3337824T (lt) 2015-08-17 2020-09-25 Janssen Pharmaceutica Nv Anti-bcma antikūnai, bispecifinės antigeną surišančios molekulės, kurios suriša bcma ir cd3, ir jų panaudojimas
EP4015537A1 (en) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017130223A2 (en) 2016-01-29 2017-08-03 Virocan Therapeutics Pvt. Ltd. A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
JP6959011B2 (ja) 2016-02-03 2021-11-02 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Bcmaおよびcd3に対する二重特異性を有するt細胞エンゲージ抗体コンストラクト
SG11201806261XA (en) 2016-02-17 2018-09-27 Seattle Genetics Inc Bcma antibodies and use of same to treat cancer and immunological disorders
CA3014202A1 (en) 2016-02-19 2017-08-24 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
MX2018012017A (es) 2016-04-01 2019-07-04 Kite Pharma Inc Antigeno quimerico y receptores de celulas t y metodos de uso.
JP6202480B1 (ja) 2016-04-22 2017-09-27 マツダ株式会社 車両用挙動制御装置
CN109641012A (zh) 2016-06-07 2019-04-16 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 与bcma结合的嵌合抗原受体和car-t细胞
CA3029209A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
EP3506931B1 (en) 2016-09-01 2024-07-31 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
AU2017332732B2 (en) 2016-09-22 2024-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
CA3041183A1 (en) 2016-11-02 2018-05-11 Engmab Sarl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
CN110022906A (zh) 2016-11-04 2019-07-16 蓝鸟生物公司 抗bcma car t细胞组合物
CN117357638A (zh) 2017-02-17 2024-01-09 弗雷德哈钦森癌症中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
GB201709508D0 (en) 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
EP3645568B1 (en) 2017-06-30 2022-08-17 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-b-cell maturation antigen chimeric antigen receptors with human domains
WO2019025983A1 (en) 2017-08-01 2019-02-07 Medimmune, Llc CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CN111526920A (zh) 2017-10-30 2020-08-11 赛诺菲生物技术公司 通过施用il-4r拮抗剂来治疗或预防哮喘的方法
CA3099066A1 (en) 2018-05-13 2019-11-21 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
KR20210020015A (ko) 2018-06-14 2021-02-23 아지노모토 가부시키가이샤 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염
CN113766931A (zh) 2019-05-01 2021-12-07 赛诺菲生物技术公司 用于通过给予il-33拮抗剂治疗或预防哮喘的方法
US20210040222A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
JP2022543815A (ja) 2019-08-05 2022-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
EP4126951A1 (en) 2020-03-27 2023-02-08 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
KR20230015965A (ko) 2020-05-22 2023-01-31 리제너론 파아마슈티컬스, 인크. Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
KR20230130681A (ko) 2021-01-08 2023-09-12 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법

Similar Documents

Publication Publication Date Title
US11964016B2 (en) Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
JP2016521713A5 (pt)
KR102679182B1 (ko) Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
RU2679920C2 (ru) Способы лечения аллергии и повышения эффективности аллерген-специфической иммунотерапии путем введения ингибитора ил-4р
JPWO2020191346A5 (pt)
JP2019531273A5 (pt)
JP2015523962A5 (pt)
PL213215B1 (pl) Zastosowanie ludzkiego przeciwciala przeciw TNFα
TW201545756A (zh) 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
JP2010513529A (ja) ヒトil−12を結合するヒト抗体及び製造方法
TW200401647A (en) Use of anti-TNF α antibodies and another drug
AU2020325021B2 (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
CN103145839A (zh) Il-12/p40结合蛋白
TW201206478A (en) Multiple-variable dose regimen for treating TNF α -related disorders
US20220220211A1 (en) Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
KR101453516B1 (ko) 항-vegf 항체를 포함하는 자가면역질환 예방 및 치료용 조성물